A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy
Husniye G. Otlu, Tong Gao, Greg P. Coffey, Jessica M. Bright, Alyssa M. A. Toda, Pamela B. Conley, Kazim Sheikh, Gang Zhang · 2026
Read A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy by Husniye G. Otlu, Tong Gao, Greg P. Coffey, Jessica M. Bright, Alyssa M. A. Toda, Pamela B. Conley, Kazim Sheikh, Gang Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13251368.txt.
Description
Husniye G. Otlu and colleagues report 2026 preclinical results for NVG-2089, a lab-made protein tested against inflammatory nerve disease. The target conditions, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy, arise when the immune system strips insulation from peripheral nerves. The standard treatment, pooled human immunoglobulin, works but needs huge doses and depends on donated plasma.
NVG-2089 is a single engineered piece of an antibody, designed to switch on calming immune receptors and expand regulatory T cells. In mice bred to develop autoimmune nerve inflammation, the protein matched immunoglobulin at preserving movement, sensation, and nerve signal strength. Treated nerves kept more insulated fibers, and immune profiling showed the expected rise in regulatory cells and inhibitory receptors. The benefit came at a far lower protein dose. The authors present the drug as a dose-efficient candidate for human trials.
Catalog record
| CREATOR | Husniye G. Otlu, Tong Gao, Greg P. Coffey, Jessica M. Bright, Alyssa M. A. Toda, Pamela B. Conley, Kazim Sheikh, Gang Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |